Craig-Hallum lowered the firm’s price target on Biodesix (BDSX) to $1.50 from $3 and keeps a Buy rating on the shares. The firm believes Biodesix is likely to sell off even further on a Q1 volume and revenue miss and lowered guidance. The company cites disruption from a sales force reorganization. Craig-Hallum expects it will take a few quarters for the company to get back on the right track, and thus has revised its estimates below the low end of the new guidance range.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDSX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue